Pinnacle Research Group

Executive Summary

Pinnacle Research Group is a privately held US-based clinical research organization (CRO) founded in 1998, with a dedicated research facility in Anniston, Alabama, and corporate headquarters in Austin, Texas. The company specializes in the conduct of Phase I through Phase IV clinical trials for both drugs and medical devices, with a particular focus on early-phase (Phase I) studies. Pinnacle’s therapeutic reach is broad, encompassing multiple disease areas. Its mission emphasizes delivering safe, ethical, and reliable trial outcomes for pharmaceutical sponsors and CROs while offering patient-participants access to novel therapies. With over 25 years of operational experience, Pinnacle has established itself as a reliable partner in the clinical development ecosystem, though it remains a smaller player relative to larger global CROs. The company’s private status and lack of recent fundraising or major public announcements suggest a steady, perhaps low-profile, operating model. Given the highly competitive CRO landscape, Pinnacle’s differentiation lies in its long-standing presence, early-phase specialization, and commitment to ethical conduct. The company’s ability to attract sponsors likely hinges on maintaining high patient recruitment and retention rates, regulatory compliance, and operational efficiency. While the clinical trials market continues to grow—driven by biopharma R&D spending and demand for outsourced services—Pinnacle must navigate pricing pressures and the need for technological adoption (e.g., decentralized trials, AI) to remain competitive. Overall, Pinnacle Research Group represents a stable but niche CRO with steady revenue from established sponsor relationships, though growth prospects may be limited without strategic investments or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Major Sponsor Contract Win (e.g., a large pharma Phase I study)60% success
• Q3 2026Facility Expansion or New Site Opening40% success
• Q2 2027Announcement of a Strategic Partnership with a Biotech30% success